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Summary 
 
 
Background 
During high-incidence influenza seasons, a robust infection prevention and control policy is 
imperative to reduce nosocomial transmission of influenza. 
Aim 
To assess the impact of Emergency Department (ED) influenza point-of-care-testing (POCT) 
and influenza-ward patient-cohorting on infection prevention and control and clinical 
outcomes.  
Methods 
Influenza POCT was operational in our adult ED from 21st January 2018 and an influenza-ward 
from 25th January 2018. A retrospective ‘before-after’ analysis was performed with pre-
intervention defined as 1st November 2017-20th January 2018 and post-intervention 21st 
January-30th April 2018. Primary outcome was rate of hospital-acquired influenza (HAI). 
Secondary outcomes included antiviral prescription and length of stay. The length of time 
inpatients remain influenza RNA detected by polymerase chain reaction (PCR) was also 
analysed. 
Findings 
There were 654 inpatients with confirmed influenza during the 2017/18 influenza season, 223 
pre- and 431 post-intervention. Post-intervention, there was fewer HAI per day (0.66 v 0.95, 
p<0.0001), median length of stay in days was shorter (5.5 v 7.5, p=0.005) and antiviral 
prescription more frequent (80% v 64.1%, p<0.0001). Cohorting released 779 single rooms for 
use elsewhere in the trust. The fixed-probability of being PCR-negative by the next day (P) was 
0.14(95% CI, 0.12-0.16) for immunocompetent patients. This implies half of immunocompetent 
patients are PCR-negative by day 5 post-diagnosis (95% CI, 5-6). 
Conclusion 
ED influenza POCT and influenza-ward patient cohorting was associated with reduced 
nosocomial transmission of influenza and improved patient flow. A policy of retesting 
immunocompetent patients at day 5 post-diagnosis could allow half to come out of respiratory 
isolation earlier. 
 
Introduction 
The case fatality rate associated with influenza in hospitalised patients remains 3.4-8.3%[1] and 
may be twice as high when influenza is hospital-acquired (HAI) compared to community-
acquired (CAI) [2]. Nosocomial influenza outbreaks lead to increased bed occupancy and closed 
wards during winter months, with significant financial implications.[3] A robust infection 
prevention and control policy to reduce nosocomial transmission is therefore imperative, 
especially during years of high influenza incidence, such as the 2017/18 influenza season [4][5]. 
The influenza strategy at our large tertiary-centre teaching hospital focused around five 
principles (Table I). 
The Roche Cobas® Liat® influenza A/B & RSV assay (Roche, Switzerland) (Liat) is an automated 
multiplex PCR system with a rapid turn-around time of 20 minutes [6]. Previous studies have 
found its performance excellent, with a sensitivity/specificity in the region 100%/97.1-100% 
for influenza A, and 97.8%-100/99.5-99.7% for influenza B [7][8]. 
We implemented influenza A/B point-of-care-testing (POCT) with Liat into the Emergency 
Department (ED) and patient-cohorting in a designated influenza-ward half-way through the 
influenza season. After the end of the influenza season a service evaluation was conducted to 
assess the impact of these new services on patient care and infection control. Outcomes 
included rates of HAI, prescription of antivirals and length of stay. Achievement of respiratory 
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isolation, and an assessment of bed-days lost from influenza related blocked-beds and single 
room bed-days saved from patient-cohorting was undertaken. The data also provided the 
opportunity to estimate the length of time inpatients remained influenza positive by 
polymerase chain reaction (PCR). 
 
Methods 
 
Design and study population 
 
All inpatients with confirmed influenza at St. George’s Hospital in South West London during the 
2017/18 influenza season were included in this study. Our influenza strategy (Table I) was 
facilitated and overseen through daily infection prevention and control meetings and recording 
of all influenza cases in the hospital on the patient admission system (available to all relevant 
staff). The purpose of this service evaluation was to conduct a ‘before-after’ assessment into the 
impact of ED influenza POCT and influenza-ward patient-cohorting on infection prevention and 
control and clinical outcomes. 
 
The Roche Cobas® Liat POCT assay (Roche, Switzerland) was used for the first time in the adult 
ED from 21st January to 14th April 2018. All patients being admitted with possible influenza 
were to be tested by throat swab. Negative samples were routinely re-tested in the on-site 
diagnostic laboratory by the Fast Track Diagnostics (FTD) Respiratory Pathogens 21 multiplex 
real time PCR (Fast-track Diagnotics, Luxembourg) (rPCR) assay. Positive samples were not 
routinely re-tested but many patients had subsequent samples taken soon after admission. 
These were tested either by rPCR, or the Cepheid Xpert® Xpress Flu/RSV assay (Cepheid, 
California, USA) (fPCR) where influenza was specifically queried or a rapid result required. 
 
An influenza-ward was operational from 25th January to 6th April 2018. There were four, 4-
bedded bays: male influenza A, female influenza A, male influenza B and female influenza B 
alongside seven single rooms. Bays had doors which remained closed. The ward (including staff, 
cleaners, equipment and toilets) were divided into separate influenza A and B sides. Staff shared 
common areas such as the staff room, sluice and clean utility rooms. Single rooms were used for 
those with mixed influenza A/B infection or another reason for single room. Patients considered 
appropriate for transfer onto the influenza-ward included all adults with confirmed influenza. 
Transfer was avoided for unstable patients or where the patient required care from a speciality 
other than general medicine. 
 
For the before-after analysis the pre-intervention period is defined as those patients admitted 
between 1st November 2017-20th January 2018 and post-intervention as 21st January-30th April 
2018. Admission date, rather than date of influenza diagnosis, was used because the two 
interventions concerned identification of CAI and patient flow following admission. Descriptive 
statistics of the 2016/17 season are provided for comparison. 
 
Outcomes 
 
The primary clinical outcome was the frequency of HAI per day for patients admitted either pre- 
or post-intervention. Secondary clinical outcomes included rates of antiviral prescription, 
length of stay and 30-day all-cause mortality. 
 
Secondary infection prevention and control outcomes included influenza-related blocked beds 
days per day and an estimation of single room bed-days saved by patients being in a bay on the 
influenza-ward, rather than a single room elsewhere in the trust. A ‘blocked bed-day’ describes 
an unoccupied bed that is closed to admissions for that day (e.g. because another patient in that 
bay has influenza). 
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Two sub-analyses were performed to assess the impact of ED POCT and influenza-ward 
cohorting on respiratory isolation for patients admitted with CAI. All patients with a ED POCT 
known to be a true-positive (n=76) were compared against 76 randomly-selected true-negative 
controls to assess if negative POCT results reduced single room usage. This comparison could 
not be matched for age and sex because this information was not available for all POCT results. 
The 62/76 patients admitted post positive POCT were then compared against 62 CAI controls 
(matched for age and sex) admitted pre-intervention to assess impact on the proportion of bed-
days spent in respiratory isolation during the first 5 days of admission. 
 
Data from patients with at least one subsequent swab were used within a post-hoc analysis to 
estimate time from initial PCR-positive sample to PCR-negativity to assess the appropriateness 
of our policy to re-swab patients after 5 days (and cease respiratory isolation early if negative – 
Table I). 
 
Sample testing 
 
Both rPCR and fPCR testing were performed by laboratory staff. rPCR testing was performed 
using the Roche Flow solution. This comprises a Hamilton primary sample handler and PCR set-
up (PSU) system (Hamilton Company, USA) and Roche MagNA Pure 96 nucleic acid extraction 
system and Light Cycler 480 real time PCR system (Roche, Switzerland). fPCR is a cartridge-
based molecular device capable of detecting influenza A/B and RSV. 
 
Data collection 
 
The infection prevention and control influenza-database (kept for outbreak management) was 
cross-referenced against rPCR/fPCR data extracted from our Laboratory Information 
Management system, to create an excel spreadsheet of all patients hospitalized with confirmed 
influenza during the 2016/17 and 2017/18 seasons. Electronic patient records, discharge 
summaries/medications and pharmacy records were reviewed. ‘Severely immunosuppressed’ 
was defined as per Public Health England (PHE) guidelines – i.e. including patients undergoing 
chemotherapy for malignancy, transplant recipients, HIV infected patients with CD4<200/μl 
and patients receiving high dose systemic corticosteroids or other immunosuppressive 
therapies [9]. POCT results were obtained from an ED log book. CAI was defined as influenza 
confirmed by PCR <72 hours after admission, HAI ≥ 72 hours. This standard definition[10] is 
based upon the usual in-vivo incubation period for influenza being 1-3 days[11] and a practical 
solution to the fact that information pertaining to symptom onset was not readily available. 
Data on influenza-related ward bay and bed closures was obtained from an electronic system 
‘Real-time Experience’ (‘RaTE) into which data was entered regularly throughout the influenza 
season by the infection prevention and control nursing team. 
 
Statistical analysis 
 
For all comparisons between pre- and post-intervention periods, P values were calculated using 
chi-squared test for categorical data, and Mann–Whitney U test for continuous data using IBM® 
SPSS® Statistics. 
 
For the ‘time until PCR-negativity’ analysis time from first PCR-positive swab (t0) until last 
positive swab (t1) informed the minimum possible time of possible PCR-positivity (lower 
bound). Time from t0 until first PCR-negative swab (t2) informed the maximum time of PCR-
positivity (upper bound). For the raw data analysis, the midpoint between t1 and t2 provided 
an estimate of the duration of PCR-positivity for each patient. This was then plotted in a 
cumulative manner to display the proportion of patients PCR-negative per day post diagnosis 
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for the immunocompetent and severely-immunosuppressed separately. Our approach to those 
without both a t1 and t2, is discussed under Limitations below. 
 
For the statistical model, the probability of being PCR-negative by the next day ‘P’ was  
estimated by maximum likelihood using R’s ‘optim’ function. Akaike information 
criterion (AIC) favored a geometric model whereby P was of a fixed value over a mixed effects 
model that allowed P to vary for each patient and a semi-parametric approach whereby P was 
allowed to vary over time. 
 
 
Ethics 
  
As a service evaluation of our influenza strategy, using only existing data collected during 
routine clinical practice, formal approval of the protocol by an ethics review board was not 
necessary. 
 
Results 
 
Influenza was detected in 268/975 (27.5%) of ED/inpatients tested pre-intervention and 555/ 
1651 (33.6%) post-intervention. There were 654 inpatients with confirmed influenza during 
the 2017/18 influenza season compared to 154 the year before. Of these, 223 were admitted 
pre- and 431 post-intervention (Table II). The 2017/18 cohort was older than the previous year 
(median age 71 v 60 years, p<0.0001) with more influenza B (46.5% v 7.1%, p < 0.0001). 
 
Post-intervention 226/317 (71.3%) of adults admitted with CAI received a POCT, of which 208 
(92%) were positive. There were no significant differences in age, gender, rates of severe 
immunosuppression or influenza strain comparing those admitted pre- and post-intervention 
(Table II). 
 
The rate of HAI per day was lower post-intervention (0.66 v 0.95, p<0.0001). This was despite 
there being a higher reported rate of influenza reported in the community in the post 
intervention period, 290.9 v. 236.5 GP influenza-like-illness (IFI) consultations in England per 
100,000 in each period[4,5] (Table II). Comparing pre- to post-intervention for all inpatients 
with influenza, median length of stay in days was shorter (5.5 v 7.5, p < 0.0001) and proportion 
of patients prescribed antivirals greater (80% v 64.1%, p<0.0001). There was no statistically 
significant difference in 30-day all-cause mortality (6.7 v 10.3%, p =0.11). 
 
The sub-analysis shows single room usage within 48 hours of admission was lower in those 
admitted following a negative POCT in the ED (21.5% v. 74.8%, p<0.0001) (Table III). The 
number of admission bed-days within 48 hours of admission is less than 76x2(152) for both 
arms because some patients were discharged after one day. 74.8% of patients with known 
influenza were placed in single room because many were isolated on the cohort ward. Patients 
admitted with CAI with a positive POCT for influenza, spent a higher proportion of bed-days in 
respiratory isolation during the first five days of admission than those with CAI admitted pre-
intervention (89.6% v 79.8%, p=0.003) (Table IV). 
 
There were more influenza-related blocked bed-days per day post intervention, partly because 
of the cohort ward (5.05 v 2.77, P<0.0001). Over its 71 days of being operational, the influenza-
ward had 1000 potential bay bed-days. Over 46 days sampled, 143 bay beds were unoccupied. 
By this we can estimate that over the 71 days 221 bay beds were unoccupied ((143/46)x71 = 
221). Therefore, the influenza-ward released approximately 779 single room bed-days (1000-
221) for use elsewhere in the trust at the cost of 221 lost bay bed-days. 
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During the 2017/18 season, 316(48.3%) of patients hospitalised with influenza had at least one 
subsequent swab and so were included in the ‘time until PCR-negativity analysis’. Of these 
42(13.3%) had severe immunosuppression. 161 patients had an initial rPCR and so CT value 
recorded. Figure 1 displays both the raw data and statistical model for those with severe 
immunosuppression and without. 
 
The fixed-probability value of being PCR-negative by the next day (P) was not significantly 
lower for those with severe immunosuppression 0.10 (95% CI, 0.07-0.14) than those without 
0.14 (95% CI, 0.12-0.16) (p=0.052). This implies a median duration of PCR-positivity of 4 days 
for immunocompetent patients i.e. by day 5 post diagnosis 50% will be PCR negative (t50% = 
day 5, 95% CI, 5-6). For immunocompromised t50% = day 7 (95% CI 5-9). Initial CT value did 
not impact P (p=0.27). 
 
Discussion 
 
This is the first real-world evaluation into the impact of ED influenza POCT and patient-
cohorting on both clinical and infection prevention and control outcomes in a high-incidence 
setting. In agreement with PHE data,[4][5] there was more influenza and a greater proportion of 
influenza B during the 2017/18 season than the year before (Table II). 
 
Post-intervention, there were fewer cases of HAI (Table II), despite a greater number of 
reported CAI. Because of the vulnerable population involved, HAI is associated with a 
substantial morbidity and mortality so this is a significant finding [12]. It is made even more 
impressive by the fact that nosocomial outbreaks are more likely the more influenza that is 
coming into the hospital (in the form of CAI admissions, but also staff and visitors)[10]. 
 
Interestingly, rate of HAI per day was greater in the 2017/18 pre-intervention period compared 
to the 2016/17 season (0.95 v. 0.2, p<0.0001) which may indicate the potential impact the high 
incidence of influenza would have made, had it not been for the interventions. 
 
Reduction in HAI may result from improvements in respiratory isolation. POCT and availability 
of beds on the influenza-ward increased the rates of respiratory isolation in the first five days of 
admission when patients are most infectious (Table IV). Influenza transmission routes remain 
controversial[11][13] but respiratory isolation focusing on preventing both droplet and short-
range airborne transmission remains the goal of most guidelines [14][15]. Ideal duration of 
isolation is more contested. PHE guidelines advise that inpatients with risk factors for 
prolonged viral shedding (e.g. old age, significant co-morbidity, immunosuppression, 
pneumonia) should remain in isolation until 24 hours after resolution of symptoms, rather than 
rely on any five-day-rule [16] [17]. Inpatients may have cough or fever for reasons other than 
influenza leading to unnecessary isolation. Our policy involved re-swabbing 5 days from 
diagnosis and lifting respiratory isolation early if PCR-negative (Table I). The ‘time until PCR-
negativity analysis’ suggests this was not unreasonable because half of patients were PCR-
negative by this time (Figure 1). These results align with previous studies showing that by day 
seven of illness (rather than post-diagnosis) half of inpatients are PCR-negative [18]. Our 
decision to treat those with severe immunosuppression differently is because these patients 
have elsewhere been shown to shed virus for longer [10]. In our data t50% was day seven for 
immunocompromised patients but this difference was not statistically significant (p=0.052). 
The deviations of the model from the raw data curve at days 3 and 8 most likely stem from the 
five-day testing policy (i.e. if someone tested negative on day five then the t1-t2 midpoint would 
be day 3). Given that the raw data is probably heavily distorted by the testing policy the 
geometric model may more accurately estimate true ‘time until PCR-negativity’ in our 
population. 
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The link between ‘PCR-negativity’ and ‘end of infectiousness’ is not well established but non-
infective influenza nucleic acids remain detectable by PCR after viral culture becomes negative, 
and animal models suggest that it is viral culture that correlates best with the presence of 
infective virions [19]. PCR-negativity is therefore likely to over-estimate, not underestimate, 
infectivity. This means our policy to lift isolation early in those that are PCR-negative is 
reasonable (whereas a policy requiring PCR-negativity may not be). 
 
This policy did not apply to the severely immunocompromised who were required to have three 
PCR-negative swabs, and would ideally stay in a single room even if non-infectious. Our re-swab 
policy generally utilized fPCR so all patients were known to be RSV PCR-negative before de-
isolation. For symptomatic patients, it may be prudent to utilize a panel such as rPCR that 
detects a range of respiratory pathogens in case of co-infection. 
 
In agreement with prior studies[20][21], we found that prescription of neuraminidase 
inhibitors (NAI) increased post-introduction of an influenza POCT (Table II). Whilst no 
randomized control trials (RCTs) have examined the effectiveness of NAI in inpatients, a large 
meta-analysis of cohort data from the H1N1 pandemic suggested that NAI use within 48H of 
symptoms may reduce mortality by as much as 50% - adjusted odds ratio (aOR) 0.50 (95% CI, 
0.37-0.67%, p< 0.0001) [22]. No benefit was found for treatment started after 48H, except in a 
subgroup of adults admitted to critical care. A Spanish study analyzing data across 6 influenza 
seasons also found NAI had greatest impact if given within 48H, but benefit for administration 
up to five days post symptoms onset was observed[23]. ED influenza POCT may have increased 
antiviral prescriptions for those with confirmed influenza by enabling diagnosis within 48H of 
symptom onset [20]. 
 
 
Increased antiviral prescription may have contributed towards reduction in HAI by reducing 
ongoing transmission. NAIs reduce duration of symptoms by around a day[24] and a study of 
adults hospitalised with influenza found the proportion still PCR-positive by day 7 fell from 
57.1% to 14.3% when NAIs were given within 48H (p=0.004) [18]. Perhaps also because of the 
use of antivirals, we found reduction in length of stay comparable to a previous RCT [21] but 
this may also reflect the greater proportion of CAI in the post-intervention group. Studies failing 
to show an effect on length of stay have generally had delays between presentation and the 
POCT result[25] and this is why POCT may be best situated in the ED. 
 
In the absence of ED POCT testing, patients with possible influenza are often placed in a single 
room for 24-48 hours until laboratory testing confirms or refutes the diagnosis. In our study, 
patients with negative POCT results were isolated in single rooms less often than those with 
positive POCT results (21.5% v. 74.8%, p<0.0001) (Table III). Furthermore, the influenza-ward 
admitted 168 patients over its duration, releasing 779 single room bed-days for use elsewhere 
in the trust. Hospital single rooms are a precious resource in winter months so measures to  
prevent influenza POCT increasing single room usage are essential [21]. 
 
The benefits of an influenza-ward may not be as great during years of lower influenza 
prevalence or when there is less pressure on hospital beds. Patient-cohorting is unlikely to be 
appropriate if isolating all cases in single rooms remains feasible [15]. Diligence was required 
during the periods when the influenza-ward was transitioning in and out of operation to 
prevent nosocomial transmission of influenza [10]. Our results may not be reproducible without 
rapid diagnostics for influenza or the constant supervision of an experienced and dedicated 
infection prevention and control team. 
 
Limitations 
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This study supports the effectiveness of a comprehensive influenza strategy ‘as a whole’, 
however, being an observational and uncontrolled analysis, it cannot demonstrate that the two 
interventions caused the outcomes measured, either individually or together. There remains the 
possibility of a time bias whereby staff were more familiar and organized at implementing other 
elements of the influenza strategy (such prescribing antivirals) as time went on independent of 
the two interventions. This could, however, be seen as testament to the impact of the strategy as 
a whole. 
 
Another caveat is that there were 28 patients that were diagnosed with HAI post-intervention 
but admitted pre-intervention and so are counted under the pre-intervention arm. However, 
those diagnosed with HAI in the pre-intervention period but admitted prior to November 1st 
were similarly not included under the pre-intervention arm. It is important to consider that the 
perceived lower rates of HAI in the post-intervention period may reflect diminishing incidence 
of influenza in April. However, the absolute number of HAI was lower post-intervention and 
there were more GP (IFI) consultations in this period. 
 
There are important limitations of the ‘time until PCR-negativity analysis’ because data was not 
collected through re-swabbing at regular intervals but rather a post-hoc analysis of swabs taken 
in clinical practice. There were patients with both a t1 and t2 (n=94), t1 but no t2 (88), t2 but 
no t1 (n=134) and neither t1 nor t2 (n=338). 
 
Patients with neither t1 nor t2 were excluded as they contribute little information to the model 
and largely represent those discharged from hospital before five days. Those remaining in the 
analysis will therefore represent the ‘sicker’ patients – who may remain PCR-positive for longer. 
This means the results are highly applicable for use in guiding hospital infection prevention and 
control policies which are only concerned with inpatients. 
 
Those with t1 but no t2 were included to inform the lower bound (to exclude those whose 
second/last swab was positive would overestimate P). For these patients t2 was taken as t1+5 
days. This assumes that the lack of further swab is because the patient recovered, and had they 
been re-swabbed five days later they would have been PCR-negative. The alternative of taking 
t2 as infinite would underestimate P. Those with t2 but no t1 were included to inform the upper 
bound (to exclude those whose second/last swab was negative would underestimate P). For 
these patients t1 was taken as t0. 
 
A sensitivity analysis was performed to assess the impact of these assumptions. Focusing on the 
immunocompetent, if patients with a t1 but no t2 are excluded, P=0.16 (95% CI, 0.14-0.18), 
t50% day 4 (95% CI, 4-5). If they are included but t2 taken as infinite P=0.11 (95% CI, 0.09-
0.12), t50% day 7 (95% CI, 6-8). If those with t2 but no t1 are excluded P=0.10 (95% CI, 0.08-
0.11), t50% day 7 (95% CI, 6-8) and if only those with both t1 and t2 are included P=0.09 (95% 
CI, 0.07-0.11) t50% day 8 (95% CI, 6-10). 
 
Ultimately any inclusion/exclusion will bias the model in one direction or another, our rational 
is described above. These limitations mean this model should not be relied upon to drive policy 
change, but accompanied by prior research[18] it provides support for a 5 day re-testing policy. 
 
Conclusions 
 
During a season with high rates of both influenza A and B, ED influenza POCT and influenza-
ward patient cohorting was associated with significant reduction in nosocomial transmission of 
influenza and released 779 single rooms for use elsewhere in the trust. A policy of retesting 
immunocompetent patients at day 5 post-diagnosis could allow as many as half to come out of 
respiratory isolation early. 
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Table I Five key principals of influenza strategy 
Diagnosis Isolation Treatment & Prophylaxis Contacts Outbreaks 
Patients being admitted, inpatients 
and staff with possible influenza to be 
tested as soon as possible. 
 
Laboratory testing performed by Fast 
Track Diagnostics (FTD) Respiratory 
Pathogens 21 multiplex PCR 
(henceforth rPCR) and Cepheid Xpert 
Xpress Flu/RSV assay (henceforth 
fPCR). 
 
Laboratory testing operational seven 
days a week with twice daily rPCR 
runs and rapid fPCR testing for urgent 
cases. 
 
Liat POC testing operational in ED 
from 21/1/18-14/1/17. 
Inpatients with possible influenza 
transferred into a single room and staff to 
refrain from working duties whilst 
awaiting test result. 
 
Inpatients with confirmed influenza 
transferred into respiratory isolation and 
staff with confirmed influenza to refrain 
from working duties. 
 
Respiratory isolation achieved by use of 
appropriate personal protective 
equipment (PPE) by staff and transfer of 
patient into either: 
 A single room 
 A bed on the influenza-ward if 
appropriate 
 
Influenza-ward fully operational from 
25/1/18-6/4/18: divided into 4x4 bedded 
bays by gender/influenza strain alongside 
seven single rooms (see ‘Methods’). 
 
Inpatients and staff with confirmed 
influenza re-tested five days after first 
swab by fPCR. 
 
Isolation lifted if immunocompetent and 
either: 
 Symptom free at seven days from 
diagnosis or 
 Influenza not detected by fPCR 
(whichever comes first) 
 
Isolation lifted if immunocompromised 
and influenza no longer detected by fPCR 
on three sequential occasions. 
Treatment with antivirals 
(oseltamivir/zanamivir) 
offered to all patients with 
confirmed influenza as per PHE 
guidelines. 
 
Treatment also offered to all 
staff with confirmed influenza. 
 
Prophylaxis offered to 
asymptomatic staff working on 
outbreak/cohort wards. 
 
Multi-faceted approach to 
encourage high uptake of 
vaccination (>90%) in patient-
facing staff. 
Inpatients in ‘close proximity’ to a case 
of confirmed influenza (e.g. same bay) 
for at least four hours designated as a 
‘contact’. 
 
Contacts with symptoms/signs of 
possible influenza tested and managed 
as above. 
 
Bays containing contacts closed to 
further admissions. Contacts not to 
transfer into a new bay (only single 
room/discharge). 
 
Prophylaxis with oseltamivir offered to 
all contacts. 
 
Patients remain designated a ‘contact’ 
until either: 
 They are diagnosed with 
confirmed influenza (and 
managed as such) 
 They have no symptoms/signs of 
possible influenza at 72 hours 
since last contact with the case or 
 They have no symptoms/signs of 
possible influenza at 48 hours 
since last contact with the case 
and they are taking oseltamivir 
prophylaxis. 
Where a patient in a bay is diagnosed with 
confirmed influenza: 
 They are transferred into respiratory 
isolation and managed as above 
 Other patients in the bay are 
designated contacts and managed as 
above 
 The bay closed to further admissions 
until free of contacts as above. 
 
Where two bays on one ward are closed due 
to the same strain of influenza the ward is 
closed to further admissions pending 
discussion at an outbreak meeting. 
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Table II Impact of ED influenza POCT and flu-ward patient cohorting on hospitalised patients with confirmed influenza  
 
2016/17 season 
(n = 154) 
2017/18 season 
(n = 654) 
P  value 
2016/17 season 
(n = 154) 
Pre-intervention 
(n = 223) 
P  value 
Pre-intervention 
(n = 223) 
Post-intervention 
(n = 431) 
P  value 
Patient characteristics          
      Median age in years, (IQR) 60 (29-79) 71 (50-82) <0.0001 60 (29-79) 72 (50-83) <0.0001 72 (50-83) 70 (50-82) 0.237 
      Male sex, n (%) 79 (51.3) 305 (46.6) 0.32 79 (51.3) 104 (46.6) 0.37 104 (46.6) 201 (46.6) 1.00 
      Severe immunosuppression, n (%) 23 (14.9) 71 (10.9) 0.16 23 (14.9) 23 (10.3) 0.18 23 (10.3) 48 (11.1) 0.75 
          
Virus strain          
      Influenza A, n (%) 143 (92.9) 343 (52.4) <0.0001 143 (92.9) 107 (48.0) <0.0001 107 (48.0) 236 (54.8) 0.1 
      Influenza B, n (%) 11 (7.1) 304 (46.5) <0.0001 11 (7.1) 112 (50.2) <0.0001 112 (50.2) 192 (44.5) 0.12 
      Influenza A&B, n (%) 0 (0) 7 (1.1) 0.20 0 (0) 4 (1.8) 0.10 4 (1.8) 3 (0.7) 0.20 
          
Outcome measures          
      HAI, n (%) 36 (23.4) 143 (21) 0.68 36 (23.4) 77 (34.5) 0.02 77 (34.5) 66 (15.3) < 0.0001 
      HAI per day, n 0.20 0.79 <0.0001 0.2 0.95 <0.0001 0.95 0.66 <0.0001 
          
      GP influenza-like-illness (IFI) consultations 
in England per 100,000, n – (A) 246 527.4  246 236.5  236.5 290.9  
          
     Influenza-related blocked bed-days, n 167 729  167 224  224 505  
     Influenza-related blocked bed-days per day, 
n - (B) 
0.92 4.03 <0.0001 0.92 2.77 <0.0001 2.77 5.05 <0.0001 
     Influenza-related blocked bed-days 
weighted by GP IFI rate - (B/A)*100, n 
0.37 0.76 0.001 0.37 1.17 <0.0001 1.17 1.74 0.003 
          
      Antivirals prescribed, n (%) 73 (47.4)* 488 (74.6) <0.0001 73 (47.4)* 143 (64.1) 0.001 143 (64.1) 345 (80.0) < 0.0001 
      Median length of admission in days, (IQR) 4.5 (1.8-11.5) 5.5 (2.5-14.5) 0.019 4.5 (1.8-11.5) 7.5 (2.5-19.5) 0.001 7.5 (2.5-19.5) 5.5 (2.5-12.5) 0.005 
      30-day all-cause mortality, n(%) 9 (5.8) 52 (7.9) 0.37 9 (5.8) 23 (10.3) 0.13 23 (10.3) 29 (6.7) 0.11 
          
2016/17 = 1st Ovember 2016 – 30th April 2017 (181 days), 2017/18 = 1st November 2017 – 30th April 2018 (181 days), Pre-intervention = 1st November 2017-20th January 2018 (81 days), Post-
intervention = 21st January 2018-30th April 20118 (100 days) 
* Pharmacy data not available (figures from discharge summaries and TTOs only) so this is likely to be an under-estimate 
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Table III Impact of POCT result on respiratory isolation for those patients that were admitted 
 POCT Result  
 Influenza detected (n = 76)a No virus detected (n = 76)b P  value 
Patient characteristics    
      Median age in years, (IQR) 61 (IQR 31-75) 54 (IQR 35-76) 0.732 
      Male sex, n (%) 37 (48.7) 38 (50.0) 0.87 
Length of stay in days, (IQR)    
    
Outcome    
      Admitted n (%) 62  (81.6) 68 (89.5) 0.17 
    
      Admission bed-days within 48 hours of  
admission, n 123 135  
     Proportion of bed-days that were single 
rooms, n (%) 92 (74.8) 29 (21.5) <0.0001 
a) All cases of known true-positive POCT results 
b) Randomly selected control group (matching for age/sex not possible as this information was not available for all POCT results) 
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Table IV Impact of POCT and flu-ward cohorting on respiratory isolation for patients admitted with CAI 
 Admitted patients  
 
Post-intervention 
(n = 62)a 
Pre-intervention 
(n = 62)b 
P  value 
Patient characteristics    
      Median age in years, (IQR) 64 (44-82) 68 (38-79) 0.842 
      Male sex, n (%) 28 (45.2) 28 (45.2) 1 
Length of stay in days, (IQR) 4 (3-10) 4 (2-7) 0.468 
    
      Admission bed-days within 5 days 
of admission, n 251 233  
      Proportion of bed-days that were 
single rooms, n (%) 225 (89.6) 186 (79.8) 0.003 
a) All cases of patients admitted post positive-POCT, where POC known true positive 
b) 62 CAI controls (matched for age and sex) admitted pre-intervention 
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Figure 1 Time until influenza PCR-negativity from first PCR-positive sample 
